Forecast horizon — calibration-scored at resolution.
The cardiovascular benefit of PCSK9 inhibition with alirocumab will be confirmed as a class effect applicable to other PCSK9 inhibitors in post-ACS patients on maximally tolerated statin therapy.
TL;DR · AI-generated
Among patients who had a previous acute coronary syndrome and who were receiving high‐intensity statin therapy, the risk of recurrent ischemic cardiovascular events was lower among those who received alirocumab than amongThose who received placebo.
Author-implied confidence
72%
Current probability
Status
DRAFT
Your probability this resolves TRUE
0% (impossible)
50%
100% (certain)
Proper-scoring-rule preview
Your position is kept on this device until you sign in.
Evidence stream
1 event · 1 snapshot
posterior drift
87% → 87% (0pp · 1 point)
Peer-reviewed paper
Apr 18, 2026
Expert reactions · 0
Sign in to post a take, cite a related claim, or flag a methodological concern.
No reactions yet. Be the first expert to post a take, cite a related claim, or flag a methodological concern.
Source publication
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
· openalex W2899997727 · s2 3bd18f4d
Semantically related
Nearest claims in the expert-corpus vector space. Ordered by cosine distance — lower is closer.
0.1344
The absolute cardiovascular benefit of alirocumab over placebo is greater in post-ACS patients with a baseline LDL cholesterol of 100 mg/dL or higher compared to those with lower baseline LDL levels.
0.1470
Alirocumab treatment is associated with a numerically lower all-cause mortality rate compared to placebo in post-ACS patients on high-intensity statins (3.5% vs. 4.1%; HR 0.85; 95% CI 0.73–0.98).
0.1545
Alirocumab added to high-intensity statin therapy reduces the composite risk of coronary heart disease death, nonfatal MI, ischemic stroke, or unstable angina hospitalization compared to placebo in patients with recent acute coronary syndrome (HR 0.85; 95% CI 0.78–0.93).
0.1751
Evolocumab added to statin therapy significantly reduced the composite primary endpoint of cardiovascular death, MI, stroke, unstable angina hospitalization, or coronary revascularization (HR 0.85; 95% CI 0.79–0.92) in ASCVD patients over a median 2.2-year follow-up.
0.1795
Evolocumab significantly reduced the key secondary composite endpoint of cardiovascular death, MI, or stroke (HR 0.80; 95% CI 0.73–0.88) compared with placebo in ASCVD patients receiving background statin therapy.
0.1823
The cardiovascular benefit of evolocumab will be shown to persist or increase with longer follow-up beyond the 2.2-year median observed in the FOURIER trial.